236: Emerging Pathways: A Kinase Involved in Multiple Rheumatic Diseases

Industry Moderator(s)

• 

  Leonard Calabrese, DO

  Board Certified Rheumatologist and the Head, Section of Clinical Immunology Department of Rheumatic & Immunologic Disease
  Cleveland Clinic
  Cleveland, OH, United States

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Chemocentryx: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Jansen: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); UCB: Consultant (Ongoing)

Industry Presenter(s)

• 

  Xavier Mariette, MD

  Université Paris-Saclay
  Le Kremlin Bicetre, France

  Disclosure(s): Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Galapagos: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing)
• JM

  Joan Merrill, MD

  OMRF Professor of Medicine
  Oklahoma Medical Research Foundation
  Oklahoma City, OK, United States

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Alumis: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia: Consultant (Ongoing); BMS: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing); Gilead: Consultant (Ongoing); GSK: Consultant (Ongoing), Grant/Research Support (Ongoing); Merck/MSD: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Provention: Consultant (Ongoing); Remegen: Consultant (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing); Xenas: Consultant (Ongoing)
• JK

  James Krueger, MD, PhD

  D. Martin Carter Professor in Clinical Investigation
  Rockefeller University
  New York, NY, United States

  Disclosure information not submitted.
• JS

  Jose Scher, MD

  New York University School of Medicine
  New York, NY, United States

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)

Please join Dr Calabrese and his colleagues in sharing their converging perspectives on the role of kinases in emerging pathways in rheumatology.


Developed and offered by Bristol Myers Squibb